ERG and PTEN by FISH
Prostate Cancer is the second most common cancer in American men. The American Cancer Society’s estimates for prostate cancer in the United States for 2013 are1:
- About 238,590 new cases of prostate cancer will be diagnosed
- About 29,720 men will die of prostate cancer
Researchers have attempted to identify the prognostic importance of a variety of genes in Prostate Cancer to tailor appropriate treatment decisions for patients based on their genetic make-up.
ERG is a transcription regulator gene that is involved in multiple cell functions. PTEN is a tumor suppressor gene commonly inactivated in multiple cancers – Prostate, Breast, Thyroid, etc.
Specific genomic alterations in ERG and PTEN have been shown to have prognostic value in Prostate Cancer progression and recurrence.